With the greater success of liver transplantation, livers from deceased donors are insufficient to meet the need for livers required for transplantation. In various parts of Asia, living related liver transplantation is the treatment for patients with end-stage liver disease. An overview of anaesthesia for both the donor and the recipient is described. Controversies involving epidural anaesthesia, blood loss prevention and blood conservation techniques in the donor are discussed. Various aspects in the anaesthetic management of the recipient are also looked at.
INTRODUcTION
The shortage of cadaveric liver donors has necessitated Asian countries like Japan and Korea to implement living related liver transplantation (LRLT) as a treatment of end-stage liver disease 1, 2 . The donors are usually healthy altruistic individuals who risk complications from major liver resection in an attempt to cure a relative. Recipients require liver transplants if they have evidence of fulminant hepatic failure, a life-threatening systemic complication of liver disease or a liver-based metabolic defect or cirrhosis with complications 3 .
LRLT is usually a semi-elective procedure. Liver procurement from the donor takes place almost concurrently as the recipient operation. It is potentially a stress on operating theatre manpower resource and facility use. Occasionally, it can be an urgent procedure if the recipient is in fulminant liver failure. This article provides an overview of the anaesthetic considerations during living related liver transplantation.
ANAEsTHEsIA FOR LIVING DONOR
A right hepatectomy 4 is performed on the donor as the left lobe of the liver lobe is not sufficient to sustain most adult liver recipients. Anaesthesia for the living donor aims to minimise the risks and discomfort associated with the procedure. Intraoperative management goals include minimising haemodynamic disturbances (chiefly secondary to compression of inferior vena cave and bleeding), monitoring and treating metabolic disturbances (metabolic acidosis) and maintaining normothermia 5 .
Preoperative Management
The healthy donor would have had a thorough physical examination, a battery of laboratory tests, imaging of the liver and psychological evaluation to determine their suitability as a donor. The donor would be informed of the risks of general anaesthesia and the risks associated with the use of invasive monitoring devices. The donor would also be advised on autologous blood donation.
The options of postoperative analgesia would also be discussed, and would include either thoracic epidural analgesia or patient-controlled analgesia (PCA) using an intravenous opioid such as morphine. As the donor would possibly have had no prior experience of a painful disease, the threshold for postoperative pain may be lower.
Epidural analgesia, if sited appropriately, has been shown to achieve good analgesia in patients undergoing major abdominal surgery 6, 7 . However, its use in liver resection is controversial as postoperatively, patients may suffer postoperative coagulation derangement 8, 9 , putting the patient at risk of developing an epidural haematoma. This complication is extremely rare. An estimated incidence is about 0.005-0.006% of cases 10 (not confined to liver resection). In the literature, there have been no reports of epidural haematoma or major neurological complications with epidural catheters in living donor hepatectomy. In a series of 242 epidurals in live liver donors, Choi et al 11 reported no neurological deficits secondary to haematoma. Similarly, Stamenkovic 9 reported no spinal or epidural haematoma in 140 patients despite coagulation disturbances postoperatively. Detractors to the use of epidural analgesia would argue that although rare, the theoretical risk, however small, still exists. It is potentially catastrophic and the donor should have all possible risks minimised. Furthermore, the number of patients in the studies which showed the safety of epidurals in hepatic resections is relatively small and under-powered.
However, intravenous morphine is also not innocuous. Altered liver function could increase the risk of toxicity with systemic opiates 12 , resulting in increased sedation and potential respiratory depression. Risks and benefits of both forms of analgesia will have to be explained to the patient who will then be able to make an informed decision.
Intraoperative Management
The anaesthetic technique of choice is a general anaesthesia with tracheal intubation and controlled ventilation of the lungs. Besides standard monitoring, the donor would require temperature monitoring, continuous intra-arterial blood pressure monitoring and central venous pressure (CVP) monitoring. One or two good sized intravenous peripheral catheters should be inserted for rapid fluid infusion in the event of rapid blood loss. A centrally placed large bore intravenous catheter may have to be considered if the donor has poor peripheral venous access.
As a sizeable part of the liver is removed, the anaesthetic drugs used should have minimal impact on liver blood flow and postoperative liver function. Halothane should be avoided because of its hepatoxic effects. Isoflurane and desflurane are not hepatotoxic and produce negligible hepatotoxic metabolites 13 . Isoflurane has traditionally been favoured for liver resections due to its preservation of regional blood flow 14 . However, the aim of extubating the donor immediately postoperatively appears to favour the use of desflurane maintenance of anaesthesia with propofol as the induction agent because of their pharmacokinetic profile. Recently, Ko et al 15 demonstrated that at 1 MAC, desflurane use was associated with higher bilirubin levels and lower glomerular filtration rates in the immediate postoperative period compared to isoflurane. Conversely, Toprak et al 16 showed that at 1 MAC, desflurane showed better postoperative hepatic labarotory tests compared to isoflurane. There were no sustained hepatic and renal dysfunction and failure in both groups of patients in both studies. Desflurane appears to have no long-term impact on hepatic or renal function.
The use of the benzylisoquinolone group of muscle relaxants like atracurium or cis-atracurium may be favoured over rocuronium or vecuronium for muscle paralysis as they have no organ-dependant metabolism and do not have any hepatotoxic metabolites. The latter two are metabolised by the liver. Intraoperative analgesia will be determined by the donor's preoperative decision whether to have a thoracic epidural inserted or to use systemic opioids.
Besides good surgical expertise, intraoperative manipulation of haemodynamics can help reduce blood loss. Excessive fluid administration should be avoided. Keeping the CVP ≤5 may reduce intraoperative blood loss and reduce graft congestion. Keeping the CVP low has been demonstrated by some authors to reduce intraoperative blood loss 17, 18 . Others have not demonstrated any significant reduction in blood loss with relatively low CVP 5, 19 . Surgeons' practice will have an impact on CVP management intraoperatively. Glyceral trinitrate (GTN) infusion can be used to treat a high CVP. Intraoperative epidural anaesthesia with general (light) anaesthesia has been shown by Feltraccos et al 20 to keep CVP low during liver resection without vasodilators. Epidural anaesthesia does not lead to changes in intravascular volume but promotes redistribution of blood. This leads to a decrease in both venous return and portal vein pressure, with a reduction in hepatic congestion. Keeping the CVP low does expose the patient to risks of intraoperative hypotension. This can be treated with small doses of vasopressors. Post-resection, the CVP can be normalised with crystalloids or colloids and the cessation of GTN if it is being Proceedings of Singapore Healthcare  Volume 21  Number 3  2012 used. However, overzealous fluid administration should be avoided to prevent congestion of the liver remnant.
In spite of these measures, major bleeding can still occur. Due to the risks of heterologous blood transfusion, it should be avoided as far as possible. In addition to pre-donation and autologous transfusion, intraoperative isovolaemic haemodilution and the use of cell salvage intraoperatively can help to avoid the transfusion of banked blood in most donors 21 . Maintaining normothermia is also crucial in helping to preserve an intact coagulation system. This can be done by infusing warm fluids, employment of patient warming devices and using warmed fluids for lavage of the abdominal cavity.
Postoperative Management
Most donors are extubated immediately postoperatively unless the surgery has been very long, the patient had received a massive blood transfusion or there had been protracted intraoperative haemodynamic instability. They are monitored closely for postoperative bleeding in the first few postoperative days. Other early complications include transient hepatic dysfunction, portal vein thrombosis, deep vein thrombosis and pulmonary embolism.
Typically, the epidural catheter is kept for three to five days as this would be the time required for the coagulation profile to return towards normal. Based on American Society of Regional Anesthesia guidelines, the epidural catheter should be removed when International Normalized Ratio (INR) is equal or less than 1.4 22 . However, the use of INR as an indicator of coagulation defect does not concur with the results from thromboelastograph (TEG). Cerruti et al 23 found that in donors who had undergone right hepatectomy, TEG demonstrated hypercoagulopathy even though platelet levels were low and INR was prolonged. In patients with acute liver injury, Stravitz et al 24 observed that despite a prolonged INR, most patients maintained haemostasis by TEG. This could be due to increased clot strength with increasing severity of liver disease, increased factor VIII levels and a commensurate decline in anti-coagulant proteins. TEG monitoring would be advantageous over INR to minimise unnecessary transfusion of fresh frozen plasma prior to the removal of the epidural catheter.
ANAEsTHEsIA FOR LIVER TRANsPLANT REcIPIENT
Liver transplant surgery can be divided into three phases. In the pre-anhepatic phase, mobilisation of the liver is followed by a total hepatectomy. During the anhepatic phase, the anastomosis of the graft portal vein to recipient portal vein occurs and this is followed by the post anhepatic phase where there is re-establishment of portal circulation through the graft. The hepatic artery anastomosis is performed next, followed by re-establishment of the biliary drainage. The recipient is exposed to sudden dramatic hypotensive episodes and acute metabolic and haemoreological disturbances in addition to those pre-existing.
Preoperative Management
Preoperative preparation optimises the recipient to tolerate these disturbances. The recipient would likely have various manifestations of endstage liver disease. Reduction in hepatocyte function results in coagulopathy, hypogonadism, hypothyroidism, impaired glucose metabolism and impaired adrenal function. Cirrhosis of the liver results in portal hypertension. The patient may develop varices, ascites, splenomegaly (ensuing thrombocytopenia), pulmonary syndromes and hepatorenal syndrome. Electrolyte disturbances (hyponatraemia and hypokalaemia) may be present, especially in patients with ascites who are on diuretics.
Portopulmonary hypertension (PPHTN) and hepatopulmonary syndrome can develop. PPHTN is diagnosed when the following criteria are satisfied: Mean pulmonary artery pressure (PAP) ≥25 mmHg at rest, pulmonary vascular resistance ≥120 dyne.s.cm 5 , pulmonary capillary wedge pressure ≤15 mmHg and the presence of portal hypertension. Most of these patients may be asymptomatic. During routine 2-D transthoracic echocardiography during the preoperative workup, the peak systolic PAP is estimated in addition to the left ventricular function. An elevated value may warrant further evaluation via right heart catheterisation. PPHTN is classified as severe when mean PAP is ≥45 mmHg, which portend high perioperative mortality 25 . Upon diagnosis, treatment should be initiated to attempt to lower PAP 26, 27 . Yassen et al 28 showed that patients with mild to moderate PPHTN demonstrated a reduced right ventricular ejection fraction especially after reperfusion but this was well tolerated. Patients who do not respond to treatment are usually excluded from the waiting list.
Hepatopulmonary syndrome (HPS) is characterised by an oxygenation defect caused by pulmonary vascular dilatation in the setting of liver cirrhosis or portal hypertension. It is a clinical triad of oxygenation defect, intrapulmonary vascular dilatation (IPVD) and liver disease. The oxygenation defect in HPS is defined as a widened age corrected alveolar-arterial oxygen gradient >15 mmHg while breathing room air at sea level. Potential recipients are screened using pulse oximetry and arterial blood gas measurement. Further investigations that follow include contrast enhanced transthoracic echocardiography or radionuclide perfusion scan to detect IPVD. No clearly effective medical therapy for HPS is available except by a successful liver transplant. Practically, screening for HPS enables the physician to identify patients who qualify for or who may deteriorate over a short time frame so as to exclude them from the waiting list or conversely be given highest priority 29 .
Hepatorenal syndrome (HRS) is defined as a potentially reversible syndrome that occurs in patients with cirrhosis, ascites and liver failure. It is characterised by impaired kidney function, marked alterations in cardiovascular function and over-activity of the sympathetic nervous system and renin-angiotensin system. Severe renal vasoconstriction leads to a decrease in glomerular filtration rate (GFR). HRS may appear spontaneously or as a result of a precipitating event 30 . Patients are screened for HRS by measuring serum creatinine and 24-hour creatinine clearance. Diagnostic criteria for HRS are: serum creatinine >133 umol/L (which corresponds to a GFR of <30 mL/min); cirrhosis with ascites; no improvement in serum creatinine after at least two days with diuretic withdrawal and volume expansion with albumin; absence of shock; no current or recent treatment of nephrotoxic drugs; and absence of parenchymal kidney disease. Treatment of HRS depends on the type of HRS 31 . Ultimately, a liver transplant is the first choice of treatment as the condition is reversible after a liver transplant. Patients will have to be counselled of the need for intraoperative haemodialysis. This would necessitate the insertion of an additional dialysis catheter.
Intraoperative Management
As most LRLT are performed electively, rapid sequence induction can be avoided unless the patient has a risk factor for aspiration or gastric outlet obstruction (huge hepatoma, gross ascites). Maintenance of anaesthesia can be achieved by a combination of volatile agents with an opiate infusion (fentanyl, sulfentanil or remifentanil) or propofol plus intermediate or short acting opioids, together with cisatracurium/atracurium. These have been reported to have few side-effects on liver function 32 .
Insertion of invasive monitoring lines and large intravenous cannulas for rapid infusion is performed after the recipient is anaesthetised. If intraoperative dialysis is planned, a catheter would usually be inserted in the groin. Haemodynamic monitoring would include an arterial line and some form of CVP monitoring. The pulmonary artery catheter (PAC) used to be a gold standard of monitoring cardiac output and pulmonary artery pressures. However, due to its propensity to cause arrhythmias 33 , there is a shift towards using less invasive means of monitoring cardiac output.
Transoesophageal echocardiography (TOE) is a less invasive option. Under skilled hands, direct visualisation of the heart allows ventricular filling and contractility to be assessed. This is particularly useful during rapid changes in haemodynamics 34 . It can help confirm the diagnosis of pulmonary air-or thromboembolism. However, the use of TOE requires experience and equipment that may not be readily available. Movement of the operative field can make obtaining steady images difficult. There may also be a risk of variceal bleeding with TOE insertion 35 . Other less invasive monitoring devices like the self-calibrating arterial pulse contour cardiac output monitoring system (FloTrac/Vigileo, Edwards, Lifesciences, Irvine, CA) have also been studied. Unfortunately, it has not been shown to be an unreliable tool for monitoring cardiac output during liver transplantation 36, 37 .
Maintaining optimal fluid balance is an ongoing challenge throughout the surgery. Much of the losses result from bleeding, although there is also significant evaporative losses and transmembrane migration of fluid. Significant blood loss occurs during the hepatectomy. The use of low CVP to reduce blood loss has been discussed earlier 17, 18 . In a retrospective study, Massicotte et al 38 found that a lower CVP during liver transplantation was associated with reduced blood transfusion. In a prospective study subsequently, they demonstrated that low central venous pressure with phlebotomy reduced blood loss during liver dissection 39 . However, lowering CVP during transplantation may increase the risk of renal injury and haemodynamic instability.
Using a cell saver can help reduce heterologous blood transfusion. However, this is contraindicated in patients with malignancy. Anti-fibrinolytics have also been used to reduce blood loss [40] [41] [42] . Their use should be guided by TEG or fibrinogen levels. Their routine use is not practised because of reports of intraoperative intracardiac thrombotic events and pulmonary thromboembolism 43, 44 .
There are no studies comparing crytalloid and colloid usage in liver transplantation. The choice of a crystalloid would favour one without lactate as a buffer. From studies done in intensive care patients, it can be inferred that crystalloids and albumin have less impact on renal function and coagulopathy compared to synthetic colloids 45, 46 . The transfusion of fresh frozen plasma and platelets should be guided by TEG as discussed earlier. If equipment is unavailable, laboratory measurements of prothrombin time, international normalised ratios, partial thromboplastin time, fibrinogen, and platelet count intraoperatively should be used in relation with clinical signs of coagulopathy. These products have been associated with increased mortality post-transplantation 47, 48 and should be used judiciously.
Re-establishment of flow through the portal vein can be associated with post-reperfusion syndrome (PRS). This was first described by Aggarwal 49 as the sudden development of hypotension occurring within five minutes of liver reperfusion, lasting at least one minute in duration and commonly associated with persistent bradycardia. The cause of this phenomenon is not totally clear, although there are theories that attribute it to the sudden relative hyperkalaemia and/or acidosis. One common predictor appears to be cold ischaemic time. Paugam-Burtz et al 50 and Xu et al 51 found that prolonged cold ischaemia time contributed to a higher incidence of PRS in cadaveric liver transplantation. If it should occur, PRS should be treated with vasopressor boluses and infusion. Prior to reperfusion, acidosis, hyperkalaemia and hypocalcaemia should be corrected.
Postoperative Management
Postoperatively, the recipient is managed in the intensive care unit. The decision to extubate the patient in the operating theatre will depend on the patient's preoperative condition and intraoperative events. The recipients are monitored closely for bleeding, hepatic artery thrombosis, portal vein thrombosis and early graft rejection. Systemic opioids are administered for postoperative analgesia. Extubated patients should be carefully observed for sedation and respiratory depression.
cONcLUsION
LRLT poses clinical management challenges to doctors. In addition, ethical dilemma may be encountered where it may be a struggle to decide whether to subject a donor to the risks of major surgery and anaesthesia for potentially suboptimal outcome. However, until we can grow a liver in the laboratory, LRLT is here to stay.
